Glazer Capital’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
Other funds holding ESPR
Glazer Capital's ESPR Position: Q2 2026 in Review
Glazer Capital opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 22,416,339 shares worth $70.8M. The stake represents 1.74% of the portfolio and ranks #11 among its holdings.
192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.
- Glazer Capital held 22,416,339 shares of Esperion Therapeutics worth $70.8M as of Q2 2026.
- Esperion Therapeutics was a new Glazer Capital position in Q2 2026.
- Esperion Therapeutics made up 1.74% of Glazer Capital's portfolio in Q2 2026, its #11 holding.
- 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.
Based on Glazer Capital's 13F filing for Q2 2026, filed 17 Aug 2026.